M
Mechthild Salzer-Kuntschik
Researcher at University of Vienna
Publications - 35
Citations - 5070
Mechthild Salzer-Kuntschik is an academic researcher from University of Vienna. The author has contributed to research in topics: Amputation & Survival rate. The author has an hindex of 20, co-authored 35 publications receiving 4675 citations. Previous affiliations of Mechthild Salzer-Kuntschik include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Stefan S. Bielack,Beate Kempf-Bielack,Günter Delling,G. Ulrich Exner,Silke Flege,Knut Helmke,Rainer Kotz,Mechthild Salzer-Kuntschik,M. Werner,Winfried Winkelmann,Andreas Zoubek,Heribert Jürgens,Kurt Winkler +12 more
TL;DR: Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis.
Journal ArticleDOI
Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Leo Kager,Andreas Zoubek,Ulrike Pötschger,Ulrike Kastner,Silke Flege,Beate Kempf-Bielack,Detlev Branscheid,Rainer Kotz,Mechthild Salzer-Kuntschik,Winfried Winkelmann,Gernot Jundt,Hartmut Kabisch,Peter Reichardt,Heribert Jürgens,Helmut Gadner,Stefan S. Bielack +15 more
TL;DR: The number of metastases at diagnosis and the completeness of surgical resection of all clinically detected tumor sites are of independent prognostic value in patients with proven primary metastatic osteosarcoma.
Journal ArticleDOI
MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration.
Inge M. Ambros,Peter F. Ambros,Sabine Strehl,Heinrich Kovar,Helmut Gadner,Mechthild Salzer-Kuntschik +5 more
TL;DR: Both ES and pPNET cells express the MIC2 gene in very high amounts, which represents a highly selective and almost unique feature of these cells, making an assignment of these tumors in one entity even more likely.
Journal ArticleDOI
Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study.
K. Winkler,G Beron,Rainer Kotz,Mechthild Salzer-Kuntschik,James F. Beck,W. Beck,W. Brandeis,Ebell W,Erttmann R,Ulrich Göbel +9 more
TL;DR: The over-all increase in CDF rate does not reach statistical significance, it does, however, for the younger (less than or equal to 12 years) and for male patients, which is assumed to be the effect of increasing the methotrexate dose from 6 to 12 g/m2 in the COSS -80 study.
Journal ArticleDOI
Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group.
Toshifumi Ozaki,Silke Flege,Matthias Kevric,Norbert Lindner,Rainer Maas,Günter Delling,Rudolf Schwarz,Arthur R. von Hochstetter,Mechthild Salzer-Kuntschik,Wolfgang E. Berdel,Heribert Jürgens,G. Ulrich Exner,Peter Reichardt,Regine Mayer-Steinacker,Volker Ewerbeck,Rainer Kotz,Winfried Winkelmann,Stefan S. Bielack +17 more
TL;DR: An operative approach with wide or marginal margins improves local control and OS and if the surgical margin is intralesional or excision is impossible, additional radiotherapy has a positive influence on prognosis.